Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: One size does not fit all

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 1, 2010, Pages 55-68

  Kwara, Awewura ^a   Ramachandran, Geetha ^b   Swaminathan, Soumya ^b  

^a BROWN UNIVERSITY   (United States)

^b NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

Author keywords

Drug interactions; Efavirenz; HIV; Nevirapine; Rifampicin; Tuberculosis

Indexed keywords

CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CLINICAL TRIAL; DRUG EFFECT; DRUG METABOLISM; HEREDITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL LITERATURE; MEDLINE; MIXED INFECTION; PHARMACOGENETICS; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; BENZOXAZINES; CHILD; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RIFAMPIN; TUBERCULOSIS;

EID: 72949096292     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903393752     Document Type: Review

References (100)

1. WHO. Global tuberculosis control- epidemiology, strategy, financing. WHO Report 2009. WHO/HTM/TB/2009411 2009. Available from: Http://www.who. int/tb/publications/global-report/2009/ pdf/full-report.pdf. [Last accessed 13 August 2009]
2. Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004;190(9):1670-1676
3. Manosuthi W, Chottanapand S, Thongyen S, et al. Survival rate and risk factors of mortality among HIV/ tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006;43(1):42-46
4. Velasco M, Castilla V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009;50(2):148-152
5. Burman WJ. Issues in the management of HIV-related tuberculosis. Clin Chest Med 2005;26(2):283-94, vi-vii
6. Kwara A, Flanigan TP, Carter EJ. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: Current status. Int J Tuberc Lung Dis 2005;9(3):248-257
7. Brinkhof MW, Egger M, Boulle A, et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007;45(11):1518-1521
8. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: Impact on treatment outcomes and implications for tuberculosis control. AIDS 2006;20(12):1605-1612
9. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008;22(15):1897-1908
10. Lawn SD, Lipman MC, Easterbrook PJ. Immune reconstitution disease associated with mycobacterial infections. Curr Opin HIV AIDS 2008;3(4):425-431
11. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352(21):2211-2221
12. Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/ transport by xenobiotics. Arch Pharm Res 2005;28(3):249-268
13. WHO. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: Towards universal access. Geneva, Switzerland: World Health Organization; 2006
14. Desta Z, Saussele T, Ward B, et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 2007;8(6):547-558
15. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003;306(1):287-300
16. Mutlib AE, Chen H, Nemeth GA, et al. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: Species differences in the metabolism of efavirenz. Drug Metab Dispos 1999 Nov;27(11):1319-1333
17. Belanger AS, Caron P, Harvey M, et al. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 2009;37(9):1793-1796
18. di Iulio J, Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 2009;19(4):300-309
19. Faucette SR, Wang H, Hamilton GA, et al. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos 2004;32(3):348-358
20. Hesse LM, Sakai Y, Vishnuvardhan D, et al. Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: Comparison with rifampicin. J Pharm Pharmacol 2003;55(9):1229-1239
21. Madan A, Graham RA, Carroll KM, et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003;31(4):421-431
22. Benedeck IH, Joshi A, Fiske WD, et al. Pharmacokinetic interaction between efavirenz and rifampin in healthy volunteers. 12th World AIDS Conference; June 28-July 3 1998; Geneva, Switzerland
23. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002;41(9):681-690
24. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (6mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006;58(6):1299-1302
25. Matteelli A, Regazzi M, Villani P, et al. Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr HIV Res 2007;5(3):349-353
26. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167(4):603-662
27. CDC. Managing drug interactions in the treatment of HIV-related tuberculosis. [online] 2007. Available from: Http://www.cdc.gov/tb/ TB-HIV-Drugs/default.htm. [Last accessed 10 July 2009]
28. Pozniak AL, Miller RF, Lipman MC, et al. BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005. HIV Med 2005;6(Suppl 2):62-83
29. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003;73(1):20-30
30. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15(1):71-75 (Pubitemid 32055781)
31. Stahle L, Moberg L, Svensson JO, Sonnerborg A. Efavirenz plasma concentrations in HIV-infected patients: Inter- and intraindividual variability and clinical effects. Ther Drug Monit 2004;26(3):267-270
32. Langmann P, Weissbrich B, Desch S, et al. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients. Eur J Med Res 2002;7(7):309-314
33. Kwara A, Lartey M, Sagoe KW, et al. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: Pharmacogenetic effect of CYP2B6 variation. J Clin Pharmacol 2008;48(9):1032-1040
34. Ramachandran G, Hemanth Kumar AK, Rajasekaran S, et al. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob Agents Chemother 2009;53(3):863-868
35. Brennan-Benson P, Lyus R, Harrison T, et al. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: One size does not fit all. AIDS 2005;19(14):1541-1543
36. Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, et al. Efavirenz trough levels are not associated with virological failure throughout therapy with 8mg daily and a rifampicin-containing antituberculosis regimen. J Antimicrob Chemother 2006;58(5):1017-1023
37. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 6mg/ day versus efavirenz 8mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 2006;20(1):131-132
38. Cabrera SE, Cordero M, Iglesias A, et al. Efavirenz-rifampicin interaction: Therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients. AIDS 2008;22(18):2549-2551
39. Patel A, Patel K, Patel J, et al. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1. J Acquir Immune Defic Syndr 2004;37(1):1166-1169
40. DiGiacinto JL, Chan-Tack KM, Robertson SM, et al. Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampin. J Clin Pharmacol 2008;48(4):518-523
41. Ren Y, Nuttall JJ, Eley BS, et al. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2009;50(5):439-443
42. Cabrera SE, Santos D, Valverde MP, et al. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob Agents Chemother 2009;53(7):2791-2798
43. Kappelhoff BS, Huitema AD, Yalvac Z, et al. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet 2005;44(8):849-861
44. Arab-Alameddine M, Di Iulio J, Buclin T, et al. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther 2009;85(5):485-494
45. Motsinger AA, Ritchie MD, Shafer RW, et al. Multilocus genetic interactions and response to efavirenz-containing regimens: An adult AIDS clinical trials group study. Pharmacogenet Genomics 2006;16(11):837-845
46. Burger D, van der Heiden I, la Porte C, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: The effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol 2006;61(2):148-154
47. Kappelhoff BS, van Leth F, MacGregor TR, et al. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005;10(1):145-155
48. Pfister M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 2003;47(1):130-137
49. Stohr W, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: Effect of ethnicity, weight and co-medication. Antivir Ther 2008;13(5):675-685
50. Kwara A, Lartey M, Sagoe KW, et al. CYP2B6 (c.516G->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol 2009;67(4):427-436
51. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. Aids 2004;18(18):2391-2400
52. Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001;11(5):399-415
53. Tsuchiya K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 2004;319(4):1322-1326
54. Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008;61(4):914-918
55. Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007;81(4):557-566
56. Nyakutira C, Roshammar D, Chigutsa E, et al. High prevalence of the CYP2B6 516G->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008;64(4):357-365
57. Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005;40(9):1358-1361
58. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005;15(1):1-5
59. Saitoh A, Fletcher CV, Brundage R, et al. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. J Acquir Immune Defic Syndr 2007;45(3):280-285 (Pubitemid 47012374)
60. ter Heine R, Scherpbier HJ, Crommentuyn KM, et al. A pharmacokinetic and pharmacogenetic study of efavirenz in children: Dosing guidelines can result in subtherapeutic concentrations. Antivir Ther 2008;13(6):779-787
61. Klein K, Lang T, Saussele T, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: Allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005;15(12):861-873
62. Mehlotra RK, Bockarie MJ, Zimmerman PA. CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: Implications for HIV/AIDS treatment. Br J Clin Pharmacol 2007;64(3):391-395
63. Riska P, Lamson M, MacGregor T, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 1999;27(8):895-901
64. Lamson MJ, Cort S, Sabo JP, et al. Assessment of Nevirapine oral bioavailability in healthy volunteers following oral and intravenous administration. Pharmacol Res 1995;12:S-415
65. Lamson MJ, Cort S, Sabo JP, et al. Effects of gender on the single and multiple dose pharmacokinetics of nevirapine. Pharmacol Res 1995;12:S-101
66. Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: A review of sex differences. Gend Med 2007;4(2):106-119
67. Combalbert J, Fabre I, Fabre G, et al. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989;17(2):197-207
68. Erickson DA, Mather G, Trager WF, et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999;27(12):1488-1495
69. Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 2001;164(1):7-12
70. Cohen K, van Cutsem G, Boulle A, et al. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother 2008;61(2):389-393
71. Alexander CS, Asselin JJ, Ting LS, et al. Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease. J Infect Dis 2003;188(4):541-548
72. de Vries-Sluijs TE, Dieleman JP, Arts D, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 2003;42(6):599-605
73. Gonzalez de Requena D, Bonora S, Garazzino S, et al. Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. Antimicrob Agents Chemother 2005;49(9):3966-3969
74. Veldkamp AI, Weverling GJ, Lange JM, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001;15(9):1089-1095
75. Kappelhoff BS, Crommentuyn KM, de Maat MM, et al. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet 2004;43(13):845-853
76. Dean GL, Back DJ, de Ruiter A. Effect of tuberculosis therapy on nevirapine trough plasma concentrations. AIDS 1999;13(17):2489-2490
77. Elsherbiny D, Cohen K, Jansson B, et al. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. Eur J Clin Pharmacol 2009;65(1):71-80
78. Ramachandran G, Hemanthkumar AK, Rajasekaran S, et al. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. J Acquir Immune Defic Syndr 2006;42(1):36-41
79. Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr 2001;28(5):450-453
80. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008;300(5):530-539
81. Oliva J, Moreno S, Sanz J, et al. Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis. AIDS 2003;17(4):637-638
82. Autar RS, Wit FW, Sankote J, et al. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther 2005;10(8):937-943
83. Manosuthi W, Ruxrungtham K, Likanonsakul S, et al. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis 2007;44(1):141-144 (Pubitemid 44969000)
84. Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis 2006;43(2):253-255
85. Avihingsanon A, Manosuthi W, Kantipong P, et al. Pharmacokinetics and 48-week efficacy of nevirapine: 4mg versus 6mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antivir Ther 2008;13(4):529-536
86. Manosuthi W, Sungkanuparph S, Tantanathip P, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: The N2R Study. Clin Infect Dis 2009;48(12):1752-1759
87. Soumya Swaminathan PC, Venkatesan P, et al. Once-daily nevirapine vs efavirenz in the treatment of HIV-infected patients with TB: A Randomized Clinical Trial. Abstract # 35. Presented at the 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009); 2009
88. L'Homme R, Warris A, Gibb D, Burger D. Children with HIV are not small adults: What is different in pharmacology? Curr Opin HIV AIDS 2007;2(5):405-409
89. Anderson GD, Lynn AM. Optimizing pediatric dosing: A developmental pharmacologic approach. Pharmacotherapy 2009;29(6):680-690
90. Chokephaibulkit K, Plipat N, Cressey TR, et al. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. AIDS 2005;19(14):1495-1499
91. Ellis JC, L'Homme RF, Ewings FM, et al. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Antivir Ther 2007;12(2):253-260
92. O'Brien DP, Sauvageot D, Zachariah R, Humblet P. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS 2006;20(15):1955-1960
93. L'Homme RF, Kabamba D, Ewings FM, et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS 2008;22(5):557-565
94. Saitoh A, Sarles E, Capparelli E, et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 2007;21(16):2191-2199
95. Kamateeka MML, Mudiope P, Mubiru M, et al. Immunological and virological response to fixed-dose nevirapine based highly active antiretroviral therapy (HAART) in HIV-infected Ugandan children with concurrent active tuberculosis infection on rifampicin-based anti-TB treatment. Abstract MOPEB089 presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, July 2009
96. Oudijk JMMH, Mulenga V, Chintu C, et al. Pharmacokinetics of nevirapine in young children during combined ART and rifampicin-containing antituberculosis treatment. Abstract LBPEB10 presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, July 2009
97. Penzak SR, Kabuye G, Mugyenyi P, et al. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med 2007;8(2):86-91
98. Ramachandran G, Ramesh K, Hemanth Kumar AK, et al. Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine. J Antimicrob Chemother 2009;63(4):841-843
99. Bakshi S, Ramachandran G, Ramesh K, et al. Study of ABCB1 polymorphism (C3435T) in HIV-1-infected individuals from South India. Br J Clin Pharmacol 2008 May;65(5):791-792
100. Bonnet M BN, Jani IV, Slawuski A, et al. Pharmacokinetic parameters of nevirapine when given without 2-weeks leading dose in tuberculosis -HIV coinfected patients receiving rifamocin: Substudy of the CARINE 12146 trial in Maputo. Abstract presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, July 2009